---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-015859"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T08:18:35.653362+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals acquires patent portfolio for $20M; issues Series C Preferred, eyes Nasdaq compliance

## Summary
- Acquired global patent portfolio from Intramont for $20M: 980k Series C Preferred Shares ($19.6M) plus $400k cash over 7 months.
- Patents cover preventive oral solutions for cold, respiratory diseases, HPV; plans ODT, toothpaste, mouthwash products.
- Series C Preferred: 6% cumulative dividend, $20 stated value, convertible at $10.00/share (2-for-1), with 4.999% conversion cap.
- Grant-back license to Intramont with 10% royalty on gross worldwide sales beginning April 2025.
- Company believes stockholders' equity now >$5M, regaining Nasdaq minimum equity requirement; still non-compliant on bid price.

## SEC filing metadata
- accession: 0001493152-24-015859
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/0001493152-24-015859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-015859
- JSON: https://secwatch.observer/filing/0001493152-24-015859.json
- Plain text: https://secwatch.observer/filing/0001493152-24-015859.txt

## Key facts
- Governance Changes
  MANGOCEUTICALS, INC.: Filed a Certificate of Designations establishing the 6% Series C Convertible Cumulative Preferred Stock, designating 6,250,000 shares with specific dividend, liquidation, conversion, voting, protective, and redemption terms (effective 2024-04-19).
  - Change: charter amendment
  - Effective: 2024-04-19
  source text: On April 19, 2024, the Company submitted for filing to the Secretary of State of Texas, a Certificate of Designations of Mangoceuticals, Inc. Establishing the Designations, Preferences, Limitations and Relative Rights of Its 6% Series C Convertible Cumulative Preferred Stock (the “ Series C Designation ”), which was filed with the Secretary of State of Texas on April 23, 2024, effective as of April 19, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/0001493152-24-015859-index.htm
- M&A Transactions
  MANGOCEUTICALS, INC. completed an acquisition involving Intramont Technologies, Inc. for $20,000,000 (closed 2024-04-24).
  - Action: acquisition
  - Counterparty: Intramont Technologies, Inc.
  - Consideration: $20,000,000
  - Closing: 2024-04-24
  source text: infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the “ Patents ”), in consideration for $20,000,000, which is payable to Intramont by (a) the issuance of 980,000 shares of the Company’s newly designated 6% Series C Convertible Preferred Stock (the “ Series C Preferred Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/0001493152-24-015859-index.htm
- Material Agreements
  MANGOCEUTICALS, INC. entered into Patent Purchase Agreement with Intramont Technologies, Inc. valued at $20,000,000 (effective 2024-04-24).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Intramont Technologies, Inc.
  - Value: $20,000,000
  - Effective: 2024-04-24
  source text: Mangoceuticals, Inc., a Texas corporation (the “ Company ”, “ we ” and “ us ”), entered into a Patent Purchase Agreement (the “ IP Purchase Agreement ”), with Intramont Technologies, Inc. (“ Intramont ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/0001493152-24-015859-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.